Directory
Portfolio companies.
34,000+ PE-backed.
Active investments and exits across European private equity portfolios.
Filter by sector, geography, status. Find the right deal comp in seconds.
Active deals
12
currently held
Exits tracked
1
hand-checked
Sectors covered
1
across the portfolio
Countries covered
1
from every market
Latest activity
Caledonia InvestmentscapitalCapital Event · capital-cancellation-shares · Capital structure change1 week agoCapital Event · capital-cancellation-shares · Capital structure change
capitalCaledonia InvestmentscapitalCapital Event · capital-cancellation-shares · Capital structure change1 week agoCapital Event · capital-cancellation-shares · Capital structure change
capitalCaledonia InvestmentscapitalCapital Event · capital-cancellation-shares · Capital structure change1 week agoCapital Event · capital-cancellation-shares · Capital structure change
capital
Elaia PartnersadminCEO change · Departure of CEO Gire, Philippe · CEO departure · leadership transition underway2 weeks agoCEO change · Departure of CEO Gire, Philippe · CEO departure · leadership transition underway
adminLauxera Capital PartnersadminBoard change · Management board member change: et Directeur général délégué Fracchia, Edoardo · Change in the management board1 month agoBoard change · Management board member change: et Directeur général délégué Fracchia, Edoardo · Change in the management board
admin13 companies matching
| Company | Sector | Geo | Investor | Entry | Hold | Status | Buyer | MOIC | |
|---|---|---|---|---|---|---|---|---|---|
arGEN-X Omnes Co-Investment | Omnes Capital | 2009 | 8yr | Exited 2017 | – | – | |||
Scenic Biotech2 periods Eir Ventures I | Eir Ventures | 2017 | 9yr | Active | – | – | |||
Citryll Health for Life Capital | Seventure Partners | 2021 | 5yr | Active | – | – | |||
Cleara Biotech Apollo Health Ventures Fund II | Apollo Health Ventures | 2022 | 4yr | Active | – | – | |||
Prilenia Therapeutics SV7 Impact Medicine Fund | SV Health Managers | 2022 | 4yr | Active | – | – | |||
ProQR Therapeutics Sofinnova Capital IX | Sofinnova Partners | 2018 | 8yr | Active | – | – | |||
Qorium Sofinnova Industrial Biotech | Sofinnova Partners | 2021 | 5yr | Active | – | – | |||
Triple Bio Nucleus Capital II | Nucleus Capital | 2026 | 0yr | Active | – | – | |||
Amarna Therapeutics Flerie Invest | Flerie | 2018 | 8yr | Active | – | – | |||
New Dawn Bio Norrsken Accelerator | Norrsken Accelerator | 2025 | 1yr | Active | – | – | |||
TargED Biopharmaceuticals Sunstone Life Science Ventures V | Sunstone Life Science Ventures | 2022 | 4yr | Active | – | – | |||
TIBEAY Biosciences MIG Fonds 18 | MIG Capital | 2026 | 0yr | Active | – | – | |||
Viroclinics Biosciences Summit Partners Portfolio | Summit Partners | 2023 | 3yr | Active | – | – |
arGEN-X
Omnes Co-Investment
NetherlandsSector
Biotech
InvestorOmnes Capital
Entry
2009
Hold
8yr
Exit
2017
Scenic Biotech
Eir Ventures I
NetherlandsSector
Biotech
InvestorEir Ventures
Entry
2017
Hold
9yr
Owners
2
Citryll
Health for Life Capital
NetherlandsSector
Biotech
InvestorSeventure Partners
Entry
2021
Hold
5yr
Cleara Biotech
Apollo Health Ventures Fund II
NetherlandsSector
Biotech
InvestorApollo Health Ventures
Entry
2022
Hold
4yr
Prilenia Therapeutics
SV7 Impact Medicine Fund
NetherlandsSector
Biotech
InvestorSV Health Managers
Entry
2022
Hold
4yr
ProQR Therapeutics
Sofinnova Capital IX
NetherlandsSector
Biotech
InvestorSofinnova Partners
Entry
2018
Hold
8yr
Qorium
Sofinnova Industrial Biotech
NetherlandsSector
Biotech
InvestorSofinnova Partners
Entry
2021
Hold
5yr
Triple Bio
Nucleus Capital II
NetherlandsSector
Biotech
InvestorNucleus Capital
Entry
2026
Hold
0yr
Amarna Therapeutics
Flerie Invest
NetherlandsSector
Biotech
InvestorFlerie
Entry
2018
Hold
8yr
New Dawn Bio
Norrsken Accelerator
NetherlandsSector
Biotech
InvestorNorrsken Accelerator
Entry
2025
Hold
1yr
TargED Biopharmaceuticals
Sunstone Life Science Ventures V
NetherlandsSector
Biotech
InvestorSunstone Life Science Ventures
Entry
2022
Hold
4yr
TIBEAY Biosciences
MIG Fonds 18
NetherlandsSector
Biotech
InvestorMIG Capital
Entry
2026
Hold
0yr
Viroclinics Biosciences
Summit Partners Portfolio
NetherlandsSector
Biotech
InvestorSummit Partners
Entry
2023
Hold
3yr